This new campaign for Erivedge features a male patient suffering from advanced BCC who doesn’t qualify for surgery or radiation. However, the time for change is now with Erivedge. It is the first and only FDA-approved Hedgehog pathway inhibitor that transforms the treatment of advanced BCC by reducing lesions in patients.

Additional examples of promotional campaigns for products marketed for the treatment of BCC are available with a subscription to CD Promo WorldWide.

Comments are closed.

Set your Twitter account name in your settings to use the TwitterBar Section.